The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.
Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process
